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Abstract Oculoleptomeningeal amyloidosis is a rare
manifestation of hereditary transthyretin (TTR) amyloidosis.
Here, we present the first case of leptomeningeal amyloi-
dosis associated with the TTR variant Leu12Pro mutation in
an African patient. A 43-year-old right-handed Nigerian
man was referred to our centre with rapidly progressive
neurological decline. He presented initially with weight loss,
confusion, fatigue, and urinary and erectile dysfunction. He
then suffered recurrent episodes of slurred speech with right-
sided weakness. He went on to develop hearing difficulties
and painless paraesthesia. Neurological examination
revealed horizontal gaze-evoked nystagmus, brisk jaw jerk,
increased tone, brisk reflexes throughout and bilateral heel-
shin ataxia. Magnetic resonance imaging showed extensive
leptomeningeal enhancement. Cerebrospinal fluid analysis
showed a raised protein of 6.4 g/dl. Nerve conduction
studies showed an axonal neuropathy. Echocardiography
was characteristic of cardiac amyloid. TTR gene sequencing
showed that he was heterozygous for the leucine 12 proline
mutation. Meningeal and brain biopsy confirmed widespread
amyloid angiopathy. TTR amyloidosis is a rare cause of
leptomeningeal enhancement, but should be considered if
there is evidence of peripheral or autonomic neuropathy
with cardiac or ocular involvement. The relationship
between different TTR mutations and clinical phenotype,
disease course, and response to treatment remains unclear.
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Introduction
Transthyretin (TTR), a serum precursor protein of amyloid,
[1] is predominantly produced in the liver. However, some
TTR is also produced in the central nervous system (CNS)
within the choroid plexus and the pigmented epithelium of
the retina [2]. Many mutations in the transthyretin gene are
known to cause familial amyloid polyneuropathy (FAP), an
autosomal dominant multisystem disease [3].
OLMA is a rare manifestation of TTR amyloidosis, char-
acterised by amyloid deposition in the meninges of the brain
and spinal cord, often with ocular involvement. Patients present
with a wide variety of neurological problems including epi-
lepsy [4], subarachnoid haemorrhage [5], hearing or visual loss
[6, 7] and headache [8]. While many TTR mutations can cause
both FAP and OLMA [6, 9, 10], the extremely rare Leu12Pro
mutation has only been associated with OLMA to date.
We described the first case of the TTR Leu12Pro
mutation in 1999 [8]. To date, the only cases described
have been in patients of European ancestry. Here, we
present the first case of the TTR Leu12Pro variant in a
patient of African origin.
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Case report
A 43-year-old right-handed Nigerian man was referred to our
centre with rapidly progressive neurological decline over a
19-month period. He presented initially in March 2011 with
weight loss of 20 kg over 3 months. Two months later, he
developed progressive confusion, fatigue, erectile difficul-
ties, urinary urgency and incontinence. In March 2012, he
suffered from recurrent episodes of slurred speech and right-
sided weakness, lasting 30 min. At his local hospital, a non-
contrast MRI head was normal, but an echocardiogram
identified a restrictive cardiomyopathy and he was started on
aspirin. The episodes were initially every 2 weeks but
increased in frequency over time. In June 2012, he devel-
oped new left-sided hearing difficulties. By October 2012,
he had developed painless paraesthesia in both feet.
There was no relevant past medical history. His father had
suffered from weight loss, erectile dysfunction and renal
problems, and died of a myocardial infarction in his 60s. His
mother died in her 50s of unknown cause. Of his four sib-
lings, the oldest brother died at age 14 but no clear cause was
established. His sister had developed deafness in her 40s.
Cardiovascular, respiratory and abdominal examination
was unremarkable. Screening cognitive testing demon-
strated anterograde memory difficulties, and impairment of
attention and concentration; the MMSE score was 21/30.
He had horizontal gaze-evoked nystagmus and a brisk jaw
jerk, but cranial nerve examination was otherwise normal.
Neuro-ophthalmological assessment was normal. Exami-
nation of the limbs revealed increased tone and brisk
reflexes in the upper and lower limbs and mild bilateral
heel-shin ataxia.
Investigations
The following blood tests were normal or negative: Full
blood count, urea and electrolytes, liver function tests,
thyroid function, cardiac enzymes, B12, folate, serum
ACE, HIV, HTLV-1, and treponemal serology, ANA,
ANCA, anti-neuronal antibodies, serum-free light chain
assay, electrophoresis and immunofixation. Urine testing
confirmed a normal creatinine clearance and no protein-
uria. On the basis of the autonomic symptoms and
restrictive cardiomyopathy, sequencing of the TTR gene
was performed, revealing that he was heterozygous for the
mutation leucine 12 proline.
Neurological investigations
Magnetic resonance imaging (MRI) of the brain and spine
showed extensive leptomeningeal enhancement over the
surface of the brain and spinal cord (Fig. 1). No signal
change was demonstrated within the underlying paren-
chyma. Susceptibility-weighted sequences revealed no
parenchymal microhaemorrhages, or evidence of sub-
arachnoid blood products. Magnetic resonance angiogra-
phy of the intra- and extra-cranial arteries was normal.
There was also evidence of mild, diffuse thickening of the
intrathecal nerve roots, and nerves of the brachial and
lumbosacral plexus (Fig. 2).
Cerebrospinal fluid (CSF) analysis showed seven white
cells (four lymphocytes and three polymorphs), CSF pro-
tein was elevated at 6.4 g/dl, with a normal glucose ratio
(3.6 mmol/l CSF and 5.9 mmol/l serum), oligoclonal bands
were not detected. Whilst the CSF Ab1-42 was depressed
(371 pg/ml, reference range 627–1,322) possibly reflecting
sequestration within CNS amyloid plaques as is seen in
Alzheimer’s disease (AD), unlike in AD the CSF tau level
was also low (107 pg/ml, reference range 146–595) miti-
gating against an ongoing neurodegenerative process. Two
further CSF examinations showed a mild pleocytosis and
persistently raised CSF protein. No organisms were cul-
tured (including mycobacterium tuberculosis) and no cel-
lular atypia was seen.
Nerve conduction studies demonstrated a mild large
fibre peripheral neuropathy in the lower limbs and a severe
small fibre neuropathy affecting both the upper and lower
limbs. Autonomic function testing showed a low resting
supine blood pressure (BP) of 101/65 mmHg and
Fig. 1 Post-gadolinium T1-weighted MR images of the cervical
spine (a, b) and brain (c), demonstrating diffuse, mildly nodular
leptomeningeal enhancement over the surface of the spinal cord, brain
stem and cerebellum (arrowheads)
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orthostatic hypotension on standing at 3 min with BP
dropping to 77/50 mmHg. A 48-h period of inpatient video
telemetry showed mild global cortical dysfunction but no
focal features or epileptiform abnormalities.
Neuro-otology investigations confirmed a mixed left-
sided peripheral and central vestibular disorder with spar-
ing of the auditory pathway. Neuropsychometry testing
showed profoundly impaired processing speed with wide-
spread cognitive impairment reflecting severe subcortical
dysfunction.
A brain biopsy was performed to confirm amyloid
deposition and exclude any other pathology. The histology
confirmed widespread amyloid angiopathy involving dura
mater, leptomeninges and neocortical blood vessels as well
as occasional vessels in the white matter. There was no
evidence of underlying malignancy or vasculitis. (see
Fig. 3).
Other investigations
Serum amyloid P component scintigraphy demonstrated
the modest amyloid deposits in the spleen and kidneys.
ECG revealed sinus rhythm with small complexes in the
inferior leads. Echocardiogram demonstrated an ejection
fraction of 51 %, mild to moderate diastolic dysfunction
with elevated filling pressures. Cardiac MRI showed
moderate left ventricular (LV) wall thickening and mod-
erate LV systolic dysfunction, along with diffuse biven-
tricular late gadolinium enhancement typical of cardiac
amyloidosis. TC-labelled DPD scintigraphy showed grade
III localization in the heart, characteristic of cardiac TTR
amyloidosis.
Arterial blood gas sampling demonstrated central
hypoventilation causing respiratory failure.
Disease course
During his inpatient stay he continued to deteriorate,
remaining very drowsy with fluctuating agitation and
confusion. Liver transplantation was considered but
excluded due to the lack of evidence for benefiting TTR
amyloidosis patients with CNS disease, along with the
presence of cardiac amyloidosis and the rapid deterioration
of the patient’s cognitive function. He was subsequently
repatriated to his local hospital. At the time of writing, he
has spent 330 days in hospital. There has been a gradual
decline in his overall condition. He has developed an atonic
bladder, with recurrent urosepsis and now has an indwell-
ing catheter.
Discussion
OLMA was first described by Goren in 1980 [11], since
then 14 TTR mutations causing leptomeningeal amyloi-
dosis have been identified [5, 7, 9–16]. Until now, these
have been found exclusively in European, American and
Japanese patients. The syndrome remains extremely rare,
with only 74 patients reported with OLMA in the literature
[4–30]. Age of onset ranges from 28 to 69 years, with a
large variation in time from presentation to time of death,
ranging from 6 months to 26 years (Table 1). The reported
cases of Leu12Pro have presented with a spectrum of
cognitive difficulties, ataxia, epilepsy, headache, peripheral
neuropathy, autonomic dysfunction, visual and hearing
loss. We report here the first case of leptomeningeal
amyloidosis in an African patient with the Leu12Pro
mutation. This patient presented with episodic symptoms
of dysarthria and right-sided weakness, on a background of
an autonomic and peripheral neuropathy, and cognitive
Fig. 2 Axial T2-weighted MR
images of the lumbosacral spine
(a, b), demonstrating mild
hypertrophy of the spinal nerve
roots. Mild prominence of the
lumbosacral plexus bilaterally is
also shown (arrows). Note the
distended urinary bladder with a
trabeculated wall (asterisk)
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decline. In addition, he also demonstrated pyramidal and
cerebellar signs on examination.
Leptomeningeal amyloid was most likely responsible
for the transient focal neurological episodes. Convexity
SAH and siderosis with TTR mutations has been described
[5], and that although we did not find SAH or siderosis,
leakage of blood products from amyloid laden fragile
leptomeningeal small vessels may have been the underly-
ing substrate for the attacks. Such transient attacks have
been described frequently in sporadic cerebral amyloid
angiopathy [31].
The contribution of TTR produced in various anatomical
sites to the disease-causing CNS amyloid deposits in
OLMA remains unclear, i.e. TTR produced locally within
the brain versus liver-derived TTR from the systemic cir-
culation. Whilst de novo oculoleptomeningeal amyloid
deposition apparently may occur after liver transplantation
has been performed in patients with TTR mutations to
remove the source of variant TTR in the blood [32], many
studies have also confirmed that wild-type TTR can con-
tinue to accumulate after liver transplant on the existing
template of amyloid associated with variant TTR. A study
of a patient who received a domino liver transplant using
an explanted FAP Val30Met patient’s liver has confirmed
that mutant TTR in the plasma does enter the brain [33].
Whilst liver transplantation has been performed in patients
with OLMA associated with various TTR mutations, pub-
lished outcome has varied and its role remains unclear.
Survival for patients with TTR Leu12Pro has ranged from
6 months to 3 years [17], while survival at 5 and 6 years
was reported with T114C [21] and T69H [23] patients,
respectively. Yamashita and colleagues also corroborated
that patients with T114C mutation may have a better
prognosis following liver transplantation. In a study of 8
patients with the T114C mutation, they found that those
receiving liver transplant had reduced mortality and mor-
bidity related to dementia and subarachnoid haemorrhage
[34].
The selectivity of Leu12Pro mutations to the central
nervous system is postulated to be due to regional differ-
ences in cell proteostasis. While unstable mutants, such as
Leu12Pro, are subject to degradation by the endoplasmic
reticulum in the liver, mutant TTR produced by the choroid
plexus binds to thyroxine (T4) causing stabilisation,
thereby preventing endoplasmic reticulum degradation.
Once the mutant TTR is released in the CSF T4 dissociates
causing destabilisation and the formation of TTR aggre-
gates [35].
Although OLMA is a rare condition, it is a devastating
and life-threatening disease. Its precise pathogenesis and
the mechanism of disease progression, which are remark-
ably rapid in our case, remain unclear as does the role of
liver transplantation.
Fig. 3 Brain biopsy of meningeal and cerebral amyloid angiopathy
Haematoxylin-Eosin stained sections (a and b) show thickened
brightly eosinophilic walls of small vessels in the leptomeninges (blue
arrowhead in a), neocortex (red arrowhead in a) and pachymeninges
(black arrowhead in b). Affected vessels are positively stained with
Congo red (c and d) which shows apple green birefringence under
polarised light (e). Ultrastructural assessment (f) confirms the
presence of haphazardly arranged amyloid fibrils in the dura mater
(blue arrowhead). TTR protein (G) is widely deposited in the walls of
the blood vessels and in addition shows patchy parenchymal deposits
with a subpial distribution. A small proportion of the vessels in brain
parenchyma also contain amyloid b deposits (H) likely to represent
co-localization of entrapped amyloid b protein. Scale bar 100 lm
(a–d); 30 lm (e); 0.5 lm (f); 50 lm (g–h)
J Neurol (2015) 262:228–234 231
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